Re-irradiation with curative intent guided by multicenter expert review and deformable dose fusion software

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial evaluates a standardized process in which radiation specialists and physicists review re-irradiation indications and cumulatively sum prior doses using MiM software to calculate EQD2. If the collective assessment suggests curative re-irradiation is feasible, a second course is planned with collected imaging and dosimetry for multidisciplinary validation. The primary goal is to determine how often this process alters the initial treatment plan. Re-irradiation with curative intent is considered even when previous dose limits might have been reached, to enable potentially beneficial outcomes. Eligibility focuses on adults requiring re-irradiation with specific disease scenarios and adequate life expectancy, while excluding certain anatomic sites and higher disease burden.”,

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years when signing the consent form
* Re-irradiation with desired curative intent (≥ 50 Gy EQD2), with volume to be irradiated totally or partially included in a previous irradiation field:

  * Oligo-metastases or oligo-progression (\< 5 metastases in less than 3 sites)
  * Second cancer
  * Isolated local recurrence
* Life expectancy \> 6 months
* Dated and signed informed consent
* Affiliation to a social security scheme or equivalent

Exclusion Criteria:

* Indication of intracranial, prostate, rectum or esophagus re-irradiation
* Diagnosis of multi-metastatic cancer
* PS ECOG ≥ 2
* Impossibility to interrupt current treatment with a tyrosine kinase inhibitor or other systemic treatment (excluding hormonal therapy) which may potentiate the rays effects (duration of wash-out according to treatment instructions)
* Pregnant or breastfeeding women
* Tutorship or curatorship or deprivation of liberty

Where it's running

• Ch Bourg En Bresse
  Bourg-en-Bresse, France Recruiting
• Centre Leon Berard
  Lyon, France Recruiting
• Institut de Cancerologie de L'Ouest
  Angers, France Not yet recruiting
• Centre Georges Francois Leclerc
  Dijon, France Not yet recruiting
• Chu Grenoble Alpes
  Grenoble, France Not yet recruiting
• Aphp Marseille Chu Timone Et Hopital Nord Marseille
  Marseille, France Not yet recruiting

Study contacts

• Principal investigator: Marie-Pierre SUNYACH — Centre Leon Berard
• Study coordinator: Marie-Pierre SUNYACH, MD
• Email: MariePierre.sunyach@lyon.unicancer.fr
• Phone: 0426556778

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Analysis of outcomes and side effects in patients receiving radiation therapy

  This study looks at the results and side effects of radiation therapy in patients at Winterthur Cantonal Hospital to see how treatment can be improved for future patients.

  Recruiting Kantonsspital Winterthur KSW · Winterthur, Canton of Zurich · NCT05192876

• Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread

  This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07893392

• Tributyrin as a dietary supplement to help prevent radiation-induced rectal injury during rectal cancer chemoradiation

  This study tests whether adding tributyrin to standard chemoradiotherapy helps prevent acute radiation-induced rectal injury in people with locally advanced rectal cancer.

  Recruiting Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07802002

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• Virtual vs in-person follow-up visits after radiotherapy

  This study tests whether telehealth follow-ups during radiotherapy are practical and satisfactory for patients and physicians, compared to in-person visits.

  Recruiting Shaukat Khanum Memorial Cancer Hospital & Research Centre · Lahore, Punjab Province · NCT07724548

• Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in Localized Rectal Cancer

  In people with locally advanced, treatment-naive rectal cancer, this study tests whether adding two immunotherapy drugs to a standard chemotherapy after short-course radiotherapy can improve tumor response.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07686640

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.